Maintenance Selinexor May Boost PFS in TP53 Wild-Type Advanced Endometrial Cancer

(MedPage Today) -- SEOUL, South Korea -- Maintenance therapy with selinexor (Xpovio) seemed to substantially extend progression-free survival (PFS) in patients with wild-type TP53 advanced or recurrent endometrial cancer, according to data from...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news